TIMOPHEI NIZHEGORODTSEV: WHEN PHARMACEUTICAL COMPANIES MANIPULATE OPINIONS OF MEDICAL WORKERS AND PATIENTS, THE GOAL IS ALWAYS OVERPRICING MEDICINE

09-06-2018 | 09:56

A representative of FAS specialized Department discussed specifics of competition on the market of pharmaceuticals

 

Head of FAS Department for Control over Social Sphere and Trade, Timophei Nizhegorodtsev took part in the XII All-Russian Forum “Health of the nation – the basis for prosperity of Russia”. Speaking at the session devoted to medicine circulation under the “Seven nosologies” programme”, he highlighted specifics of competition on the market of pharmaceuticals.

 

Price reduction is one of the benefits associated with competition. Practice shows, however, that this hard and fast rule is not always present on the pharmaceuticals market. Pharmaceuticals demand is not elastic and to a great extent it does not depend on consumers but on the opinions of health system representatives and patient communities, which are not always corroborated. As a result, although several same medicine from different manufacturers may be present on retail market at overrated prices, their prices are not going down. FAS has repeatedly faced it in its investigations”, reported Timophei Nizhegorodtsev.

 

According to Head of FAS specialized Department, not everybody is happy with fair competition. Pharmaceutical companies are attempting to manipulate registration data and opinions of medical and patient communities. Interaction between pharmaceutical companies and communities of patients and medical workers should be maximum transparent and it must be regulated.

 

Representatives of the health care system, patients organizations must report about a conflict of interests if it concerns assessments of a medicinal drug competing with a drug manufactured by a pharmaceutical companies that finance activities of those speakers. Also, all discussion participants should refer to adequate information sources. Competition on the market of medicine must be fair and transparent. When pharmaceutical companies manipulate opinions of medical workers and patients, the goal is always overpricing, and it is a serious problem, so FAS, in particular, must focus on solving it”, emphasized Timophei Nizhegorodtsev.